This finding potentially explains why cytotoxic T cells exhibit more potent cytotoxic effects in Adam2-overexpressing tumours following their in vitro expansion and self-metastasis. Non-small cell lung cancer (NSCLC) frequently involves mutations in the KRAS gene, and there is a clear need for more clinically accessible targeted therapies that specifically target the KRAS downstream signalling pathway. The gene discussed is ADAM2; the disease is non-small cell lung carcinoma.